Barclays lowered the firm’s price target on InMode (INMD) to $26 from $27 and keeps an Overweight rating on the shares. After ramping production of new products to meet demand in Q3, InMode ...

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products ...

07:19 EST InMode (INMD) sees FY25 revenue $395M-$405M, consensus $430.23M Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search ...

In a report released yesterday, Matthew Taylor from Jefferies maintained a Hold rating on InMode (INMD – Research Report), with a price target of $16.00. Discover outperforming stocks and invest ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of InMode Ltd (Symbol: INMD) entered into oversold territory, hitting an RSI reading of 29.3 ...

According to our analysis, InMode's current market capitalization is trading at less than the cash on hand plus projected 3-year cumulative free cash flow. viii This is the lowest valuation in the ...

Given the large stake in the stock by institutions, InMode's stock price might be vulnerable to their trading decisions 46% of the business is held by the top 25 shareholders Ownership research ...